Personalized vagino-cervical microbiome dynamics after oral probiotics

Chen Chen^{1,2,3,*†}, Lilan Hao^{1*}, Liu Tian¹, Liju Song¹, Xiaowei Zhang¹, Zhuye Jie^{1,2,3}, Xin Tong¹, Liang Xiao^{1,4,6}, Tao Zhang^{1,2,3}, Xin Jin¹, Xun Xu¹, Huanming Yang^{1,7}, Jian Wang^{1,7}, Karsten Kristiansen^{1,3,6}, Huijue Jia^{1,2,†}

1. BGI-Shenzhen, Shenzhen 518083, China;
2. Shenzhen Key Laboratory of Human Commensal Microorganisms and Health Research, BGI-Shenzhen, Shenzhen, China;
3. Department of Biology, Ole Maaløes Vej 5, University of Copenhagen, Copenhagen, Denmark;
4. Shenzhen Engineering Laboratory of Detection and Intervention of human intestinal microbiome, BGI-Shenzhen, Shenzhen, China;
5. China National Genobank, BGI-Shenzhen, Shenzhen 518120, China;
6. BGI-Qingdao, BGI-Shenzhen, Qingdao, 266555, China;
7. James D. Watson Institute of Genome Sciences, Hangzhou, China

* These authors contributed equally to this work.

† To whom correspondence should be addressed: H.J., C.C.

jiahuijue@genomics.cn or chenchen1@genomics.cn

Abstract

The vaginal microbiota is presumably much simpler than the gut microbiome, and oral probiotics appear as a promising means to modulate its homeostasis in the general population. Here, 60 women were followed for over a year before, during and after a probiotic containing *Lactobacillus rhamnosus* GR-1 and *L. reuteri* RC-14. Shotgun metagenomic data of 1334 samples from multiple body sites did not support colonization of the probiotics to the vagino-cervical microbiome, yet the microbiome was stable in those dominated by Lactobacilli and some individuals have likely benefited from this medication-free intervention.

INTRODUCTION

1 Lactobacilli have long been defined as the keystone species of the healthy
 2 vaginal microbiota. Lactic acid, hydrogen peroxide, biosurfactants and
 3 bacteriocins produced by these microorganisms help maintain the balance of
 4 vaginal microenvironment and wards off pathogens. A non-Lactobacillus-
 5 dominated microbial community has also been reported in women without
 6 symptoms of vaginosis, and is characterized by strictly anaerobic bacteria,
 7 such as *Gardnerella*, *Atopobium*, *Prevotella* and *Peptoniphilus*, which leads
 8 to significant increase in the risk of adverse conditions, including bacterial
 9 vaginosis (BV), preterm birth, urinary infections, human immunodeficiency
 10 virus (HIV), human papillomavirus (HPV) and other sexually transmitted
 11 infections (STIs)^{1,2,3,4,5,6,7}.

12

13 Besides fecal transplant and dietary modulation, probiotics have become a
 14 major trend for improving gut microbiome health. E.g. for the gastrointestinal
 15 tract, gut-brain axis^{8,9,10,11,12}. However, just as the vagino-cervical microbiome
 16 has received less attention as the gut microbiome, strategies for modulating
 17 the vagino-cervical microbiome is also relatively under studied.

18

19 *Lactobacillus rhamnosus* GR-1 and *L. reuteri* RC-14 are well-characterized
20 strains as supplementations in female orally consumed probiotic products.
21 The strains have also been reported to relieve colitis and osteoporosis in
22 animal models^{13,14}. However, evidence of their oral administration efficacy in
23 the prevention and treatment of vaginal infection conditions, such as BV, HIV,
24 HPV, Group B Streptococcus (GBS), remains highly debated^{15,16,17,18,19}.
25 Moreover, the route of oral administrated probiotics to the vagina and their
26 colonization in the multi-site of the human commensal microbiota remains
27 largely unexplored.

28

29 Here, we conducted a longitudinal study of 60 women to explored the effect of
30 prolonged probiotics consumption on the vagino-cervical microbiome. To
31 investigate the dynamic alternation of muti-site microbiota after taking the live
32 probiotic capsules, the tongue coat, buccal mucosal and fecal microbiome
33 composition were also analyzed.

34

RESULTS

Demographic characteristics of the cohort

35 In our cohort, 60 healthy women were recruited (median age 31, 95%
36 confidence interval (CI) 30-34; Supplementary Table 1). Samples were
37 initially collected 300 days before the intervention phase. The relations of time
38 points (before: B2, B1, B0; during: O1-O5; after: W1, W2), quantity of
39 capsules and menstrual cycle were showed (Figure 1, Supplementary Table
40 2). Vagino-cervical samples were collected at all the time points. Other multi-
41 site samples including buccal mucosa samples, tongue coat samples and
42 fecal samples were collected at eight of the time points (B0-W2). All the
43 samples were self-collected referring to a self-collection protocol, and
44 performed the metagenomic analysis with shotgun sequencing data
45 (Supplementary Figure 1). The microbial reads were extracted by filtering the

46 human reads and subsequently used for taxonomic profiling of the
47 microbiome (Supplementary Table 3).

48

Lack of oral probiotic colonization in the vagino-cervical microbiome

49 Our data showed both two probiotics were hardly present in all the body sites
50 even during intervention period (Supplementary Figure 2a, 2b). The exception
51 was *L. rhamnosus* GR-1 in fecal samples, which showed a weak colonization
52 in the time-point O4 compared to the baseline ($P = 0.01$ but $q > 0.05$,
53 Supplementary Figure 2b). Likewise, almost no change in the Shannon
54 diversity index and Bray-Curtis dissimilarity were found between baseline and
55 the probiotics period (Supplementary Figure 2c, 2d). We also collected the
56 vaginal pH accompanying the sampling, no significant differences of vaginal
57 pH were detected in all the time points ($P = 0.87$, Supplementary Figure 2e).
58 Together, this probiotics supplementation may be limited colonization in
59 vaginal or oral sites.

60

A stable vagino-cervical microbiome is resilient against Lactobacilli intake

A previous study of the oral probiotics in individuals with BV was preceded by the antibiotic metronidazole treatment²⁰, it is not clear in a more general, subclinical setting, whether the probiotic strains could really be recommended for anyone with a slight discomfort or who tested positive for potential pathogens. Compared to metagenomic data from the previous year, we classified the subjects into two groups: dysbiosis and stable, using the Bray-Curtis dissimilarity index (defined as the median Bray-Curtis dissimilarity between B2/B1 to B0) (Figure 2a). As expected, individuals of the stable group were dominated by *Lactobacillus* genera and displayed persistently lower Bray-Curtis distances, pH, Shannon alpha diversity over time compared to that of individuals in dysbiosis group (Figure 2b-2e). Thus, exogenous probiotics bacteria may be limited in

impacting the vagino-cervical microbiome in stable group. However, there was still limited efficacy of probiotics in dysbiosis group (Figure 2c, 2d). Of note, fecal microbiome of women in the dysbiosis group were also detected a less diverse but changed markedly compare to stable group (Supplementary Figure 3).

To evaluate the health condition of an independent sample, we then constructed a cross-validated random-forest model based on the vagino-cervical microbiome of the two groups (Figure 2f). 6 bacterial species included in the classifier, *Gardnerella vaginalis*, *Ureaplasma* unclassified and *Prevotella bivia* were significantly enriched in the dysbiosis group (Figure 2g). We therefore classified samples using this model. In total, 244 dysbiosis samples (Dy_s) and 166 stable samples (St_s) were classified in this cohort. To be expected, St_s were almost dominated by *L. crispatus*, *L. iners* and *L. jensenii* (Figure 2h, Supplementary Figure 4). The type transitions of samples within subjects displayed a high level of stability longitudinally, and showed no drastically transition from Dy_s to St_s during and after probiotics supplementation compared to their baselines (Figure 3, Supplementary Figure 5). Taken together, these findings point out that women consumption of the probiotics results no shedding in vagina and had no apparent effects on re-establishing a beneficial vagino-cervical microbiome.

Dynamics of Personalized vagino-cervical Microbiome

The vagino-cervical microbiome of 60 women were visualized by mapping temporal dynamics in community composition longitudinally (Figure 4). The microbiome composition of subjects in stable group appeared to be comparatively stable over time, and were typically dominated by *L. iners*, *L. crispatus* or *L. jensenii*. In these women, the slightly transitions were mostly exhibited among the different *Lactobacillus* species. The relative

abundance of non-*Lactobacillus* only resides in a small space, and showed little need to improve the vagino-cervical microbial ecosystem by consumption of the probiotics. The microbiome composition of subjects in dysbiosis group changed markedly and continuously over time. However, the relative abundance of *Lactobacillus* was observed increased during and after probiotics supplementation only in 4 subjects, including *L. crispatus* in S020, *L. iners* in S030, *Lactobacillus acidophilus* in S025, and *L. iners* and *Lactobacillus* sp. 7_1_47FAA in S065 (Figure 5a-5d, Supplementary Figure 6). All the aforementioned *Lactobacillus* were present as the endogenous bacteria from the baseline period except *L. acidophilus* (Supplementary Figure 6). These results suggested that endogenous vaginal Lactobacilli could increase after the oral probiotics

Subjects S020, S030 and S013 were detected to be infected with HPV in the baseline, but gradually be cleared away during and after their probiotic supplementation (Figure 5a, 5b, 5e). Interestingly, with the clearance away of the HPV, *Bifidobacterium* including *B. bifidum* and *B. dentium* were harboured as the dominated genus in subject S013 (Figure 5e). HPV infections were also detected in fecal samples of this subject, with a similar trend of vaginal samples in the same individual (Figure 5e). These results suggested that supplementation of these two probiotics may had some effects on HPV clearance. *Streptococcus agalactiae* (Group B *Streptococcus*), a bacterium responsible for neonatal sepsis and recently reported in placenta²¹, could be detected in 16.7% of the subjects. But the rate of vaginal *S. agalactiae* colonization did not differ significantly between baseline and the probiotics period ($P = 0.98$, Supplementary Figure 7), consistent with colonization effects in pregnancy¹⁹.

DISCUSSION

61 In this study, we provided metagenomic data for the first time following oral

probiotics supplementation. Although some volunteers showed the Lactobacilli probiotic strains in the fecal samples, there was no increase in the probiotic strains in the vaginal or oral sites, suggesting that *L. rhamnosus* GR-1 and *L. reuteri* GR-14 were not translocated from the gut to the vagina²². PCR evidence of vaginal colonization has been reported for these strains for individuals with BV, and our metagenomic data raise the possibility that endogenous vaginal Lactobacilli (*L. crispatus*, *L. iners*, etc.) have been promoted by the oral probiotics through immunological or metabolic modulation²³. We present the efficacy results from a comprehensive view of dysbiosis in the vagino-cervical microbiome. In volunteers with a Lactobacilli-dominated vagino-cervical microbiome, the microbiome is largely unchanged over one year, whether during probiotic intake or not. The dysbiosis group have a more diverse vagino-cervical microbiome and a less diverse fecal microbiome, but pH and microbiome dynamics varied between individuals. Without better ways of minimizing the individual dynamics, a much larger cohort would be needed to further analyze and predict the effects of probiotics supplementation.

It remains possible that *L. crispatus* could be more effective as an oral probiotic for the vagino-cervical microbiome. Other factors such as hormonal dynamics²⁴, seasonal changes²⁵ may also have influenced our study. Recent studies of vaginal microbial transplant (VMT) and treatment of BV using *L. crispatus* have all used a more direct topical application after standard metronidazole treatment^{26,27}. Yet, oral probiotics are more readily consumed in a subclinical setting, and may be more acceptable for pregnant women with a risk for preterm birth.

Online content

80 Any methods, additional references, Nature Research reporting summaries,
81 source data, statements of data availability and associated accession codes
82 are available at <https://db.cngb.org/search/project/CNP0001123>.

83

84 REFERENCES

- 85 1. Onderdonk, A. B., Delaney, M. L. & Fichorova, N. The Human Microbiome
86 during Bacterial Vaginosis. **29**, 223–238 (2016).
- 87 2. Fettweis, J. M. *et al.* The vaginal microbiome and preterm birth. *Nat. Med.* **25**,
88 1012–1021 (2019).
- 89 3. DiGiulio, D. B. *et al.* Temporal and spatial variation of the human microbiota
90 during pregnancy. *Proc. Natl. Acad. Sci.* **112**, 11060–11065 (2015).
- 91 4. Klatt, N. R. *et al.* Vaginal bacteria modify HIV tenofovir microbicide efficacy
92 in African women. *Science (80-.)*. **356**, 938–945 (2017).
- 93 5. Usyk, M. *et al.* PLOS PATHOGENS Cervicovaginal microbiome and natural
94 history of HPV in a longitudinal study. **1**, 1–20 (2020).
- 95 6. Mitra, A. *et al.* The vaginal microbiota , human papillomavirus infection and
96 cervical intraepithelial neoplasia□: what do we know and where are we going
97 next□? *Microbiome* 1–15 (2016) doi:10.1186/s40168-016-0203-0.
- 98 7. Anahtar, M. N., Gootenberg, D. B., Mitchell, C. M. & Kwon, D. S. Review
99 Cervicovaginal Microbiota and Reproductive Health□: The Virtue of
100 Simplicity. *Cell Host Microbe* **23**, 159–168 (2018).
- 101 8. Markey, K. A., Brink, M. R. M. Van Den & Peled, J. U. Forum Therapeutics
102 Targeting the Gut Microbiome□: Rigorous Pipelines for Drug Development.
103 *Cell Host Microbe* **27**, 169–172 (2020).
- 104 9. Zeevi, D. *et al.* Personalized Nutrition by Prediction of Glycemic Article
105 Personalized Nutrition by Prediction of Glycemic Responses. 1079–1094 (2015)
106 doi:10.1016/j.cell.2015.11.001.
- 107 10. Suez, J., Halpern, Z., Segal, E. & Elinav, E. Personalized Gut Mucosal
108 Colonization Resistance to Empiric Probiotics Is Associated with Unique Host

- 109 and Microbiome Features Article Personalized Gut Mucosal Colonization
- 110 Resistance to Empiric Probiotics Is Associated with Unique Host and
- 111 Microbiome Feat. *Cell* **174**, 1388-1405.e21 (2018).
- 112 11. Henriques, F., Ribeiro, C. & Ezra-nevo, G. ScienceDirect The diet-microbiome
- 113 tango□: how nutrients lead the gut brain axis. 122–132 (2020)
- 114 doi:10.1016/j.conb.2020.02.005.
- 115 12. Johnson, A. J. *et al.* Daily Sampling Reveals Personalized Diet- Microbiome
- 116 Associations in Humans Article Daily Sampling Reveals Personalized Diet-
- 117 Microbiome Associations in Humans. 789–802 (2019)
- 118 doi:10.1016/j.chom.2019.05.005.
- 119 13. Britton, R. A. *et al.* Probiotic *L. reuteri* treatment prevents bone loss in a
- 120 menopausal ovariectomized mouse model. *J. Cell. Physiol.* **229**, 1822–1830
- 121 (2014).
- 122 14. McCabe, L. R., Irwin, R., Schaefer, L. & Britton, R. A. Probiotic use decreases
- 123 intestinal inflammation and increases bone density in healthy male but not
- 124 female mice. *J. Cell. Physiol.* **228**, 1793–1798 (2013).
- 125 15. Hummelen, R. *et al.* *Lactobacillus rhamnosus* GR-1 and *L. reuteri* RC-14 to
- 126 prevent or cure bacterial vaginosis among women with HIV. *Int. J. Gynaecol.*
- 127 *Obstet.* **111**, 245–248 (2010).
- 128 16. Macklaim, J. M., Clemente, J. C., Knight, R., Gloor, G. B. & Reid, G. Changes
- 129 in vaginal microbiota following antimicrobial and probiotic therapy. *Microb.*
- 130 *Ecol. Heal. Dis.* **26**, 1–8 (2015).
- 131 17. Ou, Y.-C. *et al.* The influence of probiotics on genital high-risk human
- 132 papilloma virus clearance and quality of cervical smear: a randomized placebo-
- 133 controlled trial. *BMC Womens. Health* **19**, 103 (2019).
- 134 18. Yang, S. *et al.* Effect of Oral Probiotic *Lactobacillus rhamnosus* GR-1 and
- 135 *Lactobacillus reuteri* RC-14 on the Vaginal Microbiota, Cytokines and
- 136 Chemokines in Pregnant Women. *Nutrients* **12**, E368 (2020).
- 137 19. Sharpe, M. *et al.* Effectiveness of oral intake of *Lactobacillus rhamnosus* GR-1
- 138 and *Lactobacillus reuteri* RC-14 on Group B Streptococcus colonization during

- 139 pregnancy: a midwifery-led double-blind randomized controlled pilot trial. *J.*
- 140 *Matern. Fetal. Neonatal Med.* 1–8 (2019)
- 141 doi:10.1080/14767058.2019.1650907.
- 142 20. Anukam, K. *et al.* Augmentation of antimicrobial metronidazole therapy of
- 143 bacterial vaginosis with oral probiotic *Lactobacillus rhamnosus* GR-1 and
- 144 placebo controlled trial. **8**, 1450–1454 (2006).
- 145 21. de Goffau, M. C. *et al.* Human placenta has no microbiome but can contain
- 146 potential pathogens. *Nature* (2019) doi:10.1038/s41586-019-1451-5.
- 147 22. Marrazzo, J. M. *et al.* Extravaginal reservoirs of vaginal bacteria as risk factors
- 148 for incident bacterial vaginosis. *J. Infect. Dis.* **205**, 1580–8 (2012).
- 149 23. Cervantes-Barragan, L. *et al.* *Lactobacillus reuteri* induces gut intraepithelial
- 150 CD4+CD8 $\alpha\alpha$ + T cells. *Science* (80-.). **357**, 806–810 (2017).
- 151 24. Gajer, P. *et al.* Temporal Dynamics of the Human Vaginal Microbiota. *Sci.*
- 152 *Transl. Med.* **4**, 132ra52-132ra52 (2012).
- 153 25. Smits, S. A. *et al.* Seasonal cycling in the gut microbiome of the Hadza hunter-
- 154 gatherers of Tanzania. *Science* (80-.). **357**, 802–805 (2017).
- 155 26. Lev-sagie, A. *et al.* Vaginal microbiome transplantation in women with
- 156 intractable bacterial vaginosis. *Nat. Med.* doi:10.1038/s41591-019-0600-6.
- 157 27. Morris, S. *et al.* Randomized Trial of Lactin-V to Prevent Recurrence of
- 158 Bacterial Vaginosis. (2020) doi:10.1056/NEJMoa1915254.
- 159 28. Chen, C. *et al.* The microbiota continuum along the female reproductive tract
- 160 and its relation to uterine-related diseases. *Nat. Commun.* **8**, 875 (2017).
- 161 29. Fang, C. *et al.* Assessment of the cPAS-based BGISEQ-500 platform for
- 162 metagenomic sequencing. 1–8 (2018) doi:10.1093/gigascience/gix133.
- 163 30. Han, M. M. *et al.* A novel affordable reagent for room temperature storage and
- 164 transport of fecal samples for metagenomic analyses. *Microbiome* **6**, 43 (2018).
- 165 31. Pan, H. *et al.* A gene catalogue of the Sprague-Dawley rat gut metagenome.
- 166 *Gigascience* **7**, (2018).
- 167 32. Li, F. *et al.* The metagenome of the female upper reproductive tract.
- 168 *Gigascience* **7**, (2018).

- 169 33. Schmieder, R. & Edwards, R. Fast identification and removal of sequence
170 contamination from genomic and metagenomic datasets. *PLoS One* (2011)
171 doi:10.1371/journal.pone.0017288.
- 172 34. Zaharia, M. *et al.* Faster and More Accurate Sequence Alignment with SNAP.
173 (2011).
- 174 35. Truong, D. T. *et al.* MetaPhlAn2 for enhanced metagenomic taxonomic
175 profiling. *Nat. Methods* **12**, 902–903 (2015).
- 176 36. Hao, Y. *et al.* HPVViewer: Sensitive and specific genotyping of human
177 papillomavirus in metagenomic DNA. *Bioinformatics* **34**, 1986–1995 (2018).
178

179 **Acknowledgements**

180 This research was supported by the Shenzhen Municipal Government of
181 China (JCYJ20170817145523036). The authors are very grateful to
182 colleagues at BGI-Shenzhen for sample collection, and discussions, and
183 China National Genebank (CNCB) Shenzhen for DNA extraction, library
184 construction, sequencing.

185

186 **Author contributions**

187 H.J. and C.C. conceived and organized this study. C.C., L.H., L.S., and X.Z.
188 performed the sample collection and questionnaire collection. L.H., C.C., L.T,
189 and Z.J. performed the bioinformatic analyses, H.J., C.C. and X.Z. wrote the
190 manuscript. All authors contributed to data and texts in this manuscript.

191

192 **Competing interests**

193 The authors declare no competing financial interest.

194

195 FIGURE LEGENDS

196 Fig. 1. Sampling strategy of the cohort.

197 We followed 60 healthy women for over one years each. The samples were
198 classified into 10 time points: baseline (B2, B1, B0), during intervention period
199 (O1-O5) and at the end of the intervention (W1, W2), according to the
200 sampling time, quantity of capsules and menstrual cycle.

201

202 Fig. 2. The vagino-cervical microbiome characteristics in dysbiosis and 203 stable groups.

204 **a, b, c, d, e.** The 46 subjects who had complete baseline time points (B2, B1,
205 B0) were classified into two groups: dysbiosis (red) and stable (blue). **a.**
206 Group the subjects according to the Bray-Curtis dissimilarity. Purple dots,
207 distance between B2 and B0; green dots, distance between B1 to B0. stable
208 group, both dots in subjects were lower than their corresponding median
209 Bray-Curtis distance (purple line: B2-B0; green line: B1-B0). Others were
210 classified into dysbiosis group. **b.** The Bray-Curtis distance at each time point
211 relative to B0. Boxplots show median and lower/upper quartiles; whiskers
212 show inner fences. Wilcoxon ranked sum test was used to conduct
213 comparisons between two groups in each time point, an asterisk denotes q
214 <0.05 , two asterisks denote $q <0.01$, three asterisks denote $q <0.001$, four
215 asterisks denote $q <0.0001$. The Relative abundance of *Lactobacillus* spp. (**c**),
216 vaginal pH (**d**), and Shannon diversity index (**e**) were compared between two
217 groups. Kruskal–Wallis test was used to conduct temporal dynamics
218 comparisons within groups. **f.** Microbiome-based discrimination between
219 dysbiosis and stable groups. Receiver operating characteristic curve (ROC)
220 according to 138 baseline samples (B2, B1, B0) from 27 dysbiosis subjects
221 and 19 stable subjects calculated by cross-validated random forest models.
222 Area under ROC (AUC) and the 95% confidence intervals are also shown. **g.**
223 6 species with most weight to discriminate Dy_s and St_s were selected by

the models. The color of each species indicates its enrichment in Dy_s (red) or St_s (blue) or no significant direction (black), respectively. **h.** PCoA on the Dy_s and St_s based on Bray-Curtis distance. Enterotype information was shown in Supplementary Figure 2.

Fig. 3. Temporal dynamics of vagino-cervical microbiome before, during and after oral probiotics.

Color bar indicating dysbiosis subjects, stable subjects and unclassified subjects. Subject IDs are indicated on the left. **b.** Profiles of Dy_s or St_s samples for 60 subjects before, during and after oral probiotics. Each shape (hollow square, solid square or diamond) represents one sample in the time series. **c.** Box plot of Bray-Curtis dissimilarity between all pairs of samples within each subject. **d.** Box plot of Shannon diversity index of samples within each subject. Boxplots show median and lower/upper quartiles; whiskers show inner fences (**c** and **d**).

Fig. 4. Dynamics of personalized vagino-cervical microbiome.

Heatmaps of the main taxa at species levels in 60 subjects is shown. Dysbiosis group, stable group and unclassified subjects present in three lines.

Fig. 5. Vagino-cervical microbiome in five selected subjects.

The microbial composition in each vagino-cervical sample at the species level according to MetaPhlAn2 is shown in the top. Vaginal and stool HPV types below the bar graphs were identified by HPVViewer. RPKM is the abbreviation of "Reads Per Kilobase per Million reads". Samples types including Dy_s (red) and St_s (blue). Other characteristics of subjects including quantity of capsules, capsule time, menstruation, vaginal pH, sensation changes, medical information, sexual intercourse and vaginal douching is shown in the bottom of the table.

Methods

254 ***Cohort demographics***

255 With the baseline for the vagino-cervical microbiome studied from May 2017
 256 and Feb. 2018, we started the metagenomic study for oral probiotics
 257 supplementation over the course of 3 months, followed by a two-month wash
 258 out period. The commercial probiotic capsules containing *Lactobacillus*
 259 *rhamnosus* GR-1 and *Lactobacillus reuteri* GR-14, and each capsule at 2.5
 260 billion colony forming units (CFUs). The study was approved by the
 261 Institutional Review Boards at BGI-Shenzhen (IRB approval numbers 17244).
 262 60 healthy women aged from 23 to 61 were recruited in Shenzhen, China
 263 (Supplementary Table 1). Exclusion criteria included: (i) Pregnant women, (ii)
 264 consumption of probiotics or antibiotics in any form within one month prior to
 265 participation. All participants provided written informed consent at enrolment,
 266 and then received a first online questionnaire covering comprehensive
 267 demographic characteristics (Supplementary Table 1). The study design
 268 consisted of three phases, baseline (10 months), probiotic intervention
 269 (consumed 90 capsules of probiotics) and follow-up (2 months). Samples
 270 were collected three times during the baseline phase (B2-B0). Time point B2
 271 was about 10 months before probiotic intervention, and B1 was about 1.5
 272 months before probiotic intervention. B0 was the most recent time point,
 273 participants were instructed to collect samples after menses period, then
 274 began to received probiotic capsules. During the intervention phase, each
 275 participant was assigned 90 capsules of probiotics and instructed to take one
 276 capsule daily. Samples were scheduled 7 (O1), 14 (O2) days after
 277 intervention, then monthly after menses period throughout the rest of the
 278 intervention (O3, O4, O5). After intervention, two follow-up visits were
 279 scheduled monthly after menses period (W1, W2). Vaginal samples were
 280 collected at each time point using a home collection kit. Two vaginal swabs
 281 were requested, the swab head of one was put into tube with storage reagent

(ref), the other one was brushed on the pH test strips. Other three different kinds of samples (buccal mucosa samples, tongue coat samples and fecal samples) were also collected by self-sampling at all time points except B2, B1. Participants were also requested to fill in an online questionnaire at each time point. The information of questionnaire including vaginal PH value, sampling time, menstruation, sexual activity. Samples belonged to probiotic intervention were removed when the participant's average capsule of probiotics was less than 0.5 a day. Throughout the entire study 1334 samples including 322 tongue coat samples, 263 buccal mucosa samples, 436 vaginal samples and 313 fecal samples were collected.

DNA extraction and metagenomic shotgun sequencing

DNA extraction of all samples from four body sites was performed as described²⁸. Metagenomic shotgun sequencing was performed on the BGISEQ-500 platform (100bp of paired-end reads)^{29–32}. The sequencing reads of stool samples were quality-controlled using Overall Accuracy (OA) control strategy (<https://github.com/Scelta/OAFilter>), and then aligned to hg19 to remove human reads using SOAP2.22 (SOAPaligner/soap2, RRID:SCR_005503) as described previously²⁹. Stringent condition for removal of host sequences was used for tongue coat samples, buccal mucosa samples and vaginal samples³², through alignment to the hg19, hg38 and YH reference by DeconSeq³³(version 0.4.33) and SNAP³⁴. Taxonomic assignment of the high-quality metagenomic shotgun data of samples from four body sites were performed using MetaPhlAn2³⁵ version 2.7.0 with database v20. HPVViewer with the default parameters was used to detect genotyping of HPV in the high-quality metagenomic sequencing data of samples³⁶.

309 **Statistical analysis**

310 Alpha diversity and beta diversity were calculated on species relative
311 abundances using Shannon-Wiener index and Bray-Curtis dissimilarity,
312 respectively. Kruskal-Wallis test was used to make temporal dynamics
313 comparisons among different time points, including species relative
314 abundance of oral probiotics, Shannon-Wiener index, Bray-Curtis dissimilarity,
315 vaginal pH and relative abundance of *Lactobacillus* genera. Wilcoxon rank
316 sum (Mann-Whitney U) and Wilcoxon signed-rank test were used to make
317 comparisons between two groups or each of two time points. The statistical
318 significance was with a p value threshold of 0.05 and a false discovery rate
319 (FDR) threshold of $q < 0.05$.

320 To build a predictive model to identify microbial dysbiosis, the species relative
321 abundances in the baseline samples were calculated with the training set with
322 500 trees in the random Forest package (version 4.6-14). Five-fold cross-
323 validation was performed five times. The cross-validation error curves from
324 the five trials were averaged, and the minimum error in the averaged curve
325 plus the standard deviation at that point were used as the cutoff for
326 acceptable error. From the sets of species with a classification error less than
327 the cutoff, the set with the smallest number of species was chosen as the
328 optimal set, as in previous methods on the vagino-uterine microbiome²⁸.
329 Relative abundances of species in all 410 vaginal samples were used to
330 determine the optimal community types of the vagino-uterine microbiome
331 according to hierarchical clustering based on the Jensen-Shannon distances
332 and Ward linkage. And more statistical details were described in the results
333 and denoted in figure legends, including sample summary, distribution, the
334 statistical method and the statistical test used and significance.

335

336 **Data availability**

337 Metagenomic shotgun sequencing data for all samples have been deposited
338 to the (CNGB) database under the accession code CNP0001123.

339